An investigational chimeric antigen receptor T-cell therapy provided via multiple infusions induced a 100% overall response rate among adults with relapsed or refractory multiple myeloma, results from a pilot study showed.
More than half of patients who received the regimen remained disease-free 18 months after their initial round of therapy, according to data presented during European Hematology Association Hybrid 2022 Congress.
ARI0002h is an autologous, gene edited CAR T-cell therapy that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells.
“Since its FDA
